Q-omics provides the consensus-scored KRT71 profile across patient tissues and cancer cell-line models. KRT71 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KRT71 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, KRT71 RNA expression shows 11,607 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, LUSC, and TGCT as cancer lineages where KRT71 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT71 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT71 survival associations across molecular data types. KRT71 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT71 RNA expression–survival associations across cancer types. High KRT71 expression shows unfavorable associations in BLCA, MESO, LUAD and SCLC, but favorable associations in BRCA and READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for KRT71 RNA expression.
This table summarizes KRT71 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KRT71. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT71 shows lower tumor expression in KICH and PRAD and higher tumor expression in LUSC, UCEC, HNSC and COAD. The LUSC box plot shows higher KRT71 RNA expression in tumor versus normal tissue (log2 FC = +0.115, t-test p < 0.001).
This table shows molecular features associated with KRT71 in patient tissues and cancer cell lines. In patient samples, KRT71 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT71 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
